Astrazeneca (AZN) Total Non-Current Liabilities (2009 - 2026)

Astrazeneca's Total Non-Current Liabilities history runs 18 years deep, the most recent figure standing at -$34.1 billion for Q1 2026.

• In Q1 2026, Total Non-Current Liabilities rose 5.37% year-over-year to -$34.1 billion; the TTM figure through Mar 2026 stood at -$34.1 billion (up 5.37% YoY), while the FY2025 annual figure was -$34.7 billion, down 198.41% from the prior year.
• Total Non-Current Liabilities was -$34.1 billion for Q1 2026 at Astrazeneca, up from -$34.7 billion in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $35.3 billion in Q4 2024 to a low of -$41.2 billion in Q1 2022.
• Historically, Total Non-Current Liabilities has averaged -$23.3 billion across 5 years, with a median of -$34.4 billion in 2025.
• The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities increased 21.71% in 2022, then plunged 198.41% in 2025.
• A 5-year view of Total Non-Current Liabilities shows it stood at $33.1 billion in 2022, then retreated by 5.19% to $31.4 billion in 2023, then climbed by 12.37% to $35.3 billion in 2024, then slumped by 198.41% to -$34.7 billion in 2025, then grew by 1.95% to -$34.1 billion in 2026.
• The last three Total Non-Current Liabilities figures came in at -$34.1 billion (Q1 2026), -$34.7 billion (Q4 2025), and -$34.4 billion (Q3 2025), per Business Quant data.